升柏和味海参口服液防治肿瘤化疗致白细胞减少症的临床研究

Prevention and Treatment of Chemotherapy-induced Leukopenia with Shengbai Heweihaishen Oral Liquid

目的:观察升柏和味海参口服液防治肿瘤化疗引起白细胞减少症的临床疗效。方法:将126例恶性肿瘤化疗患者随机分为为3组。治疗(食疗)组43例,口服升柏和味海参口服液;对照A组41例,口服鲨肝醇及维生素B4片;对照B组42例,皮下注射重组人粒细胞集落刺激因子(rh-GSF)注射液。结果:总有效率、显效率治疗组分别为90.7%、60.5%,对照A组分别为78.0%、43.9%,对照B组分别为95.2%、73.8%。治疗组、对照B组分别与对照A组比较,差异均有非常显著性意义(P<0.01);治疗组与对照B组比较,差异无显著性意义(P>0.05)。治疗组白细胞、血红蛋白和血小板升高明显,与化疗前比较,差异均有非常显著性意义(P<0.01)。治疗组化疗完成率、化疗KPS评分等各项指标均显著优于对照A组,差异均有非常显著性意义(P<0.01);治疗组恶心呕吐发生率、血红蛋白减少发生率和血小板减少发生率亦低于对照B组,差异均有显著性意义(P<0.05)。结论:升柏和味海参口服液用于恶性肿瘤化疗后,具有升高白细胞、减少化疗毒副反应的作用。

Objective： To observe the therapeutic effects of Shengbai Heweihaishen Oral Liquid in preventing and treating chemotherapy-induced leukopenia. Methods： 126 cases with malignant tumor after chemotherapy were randomly divided into the treated group （43 eases）, control group A （41 cases） and control group B （42 eases）. Results： Compared with the control group A, there existed a significant difference （P〈 0, 01） for the treated group and the control group B. There existed no sig, nificant difference （P 〉0.05） between the treated group and the control group. The leukocyte, hemoglobin and blood platelet of the treated group increased evidently, and there existed significant difference （P〈0.01）. All indexes such as the chemotherapy finishing rates and chemotherapy KPS grades were evidently superior to those of control group A, and there existed a significant difference （P〈0, 01）. The occurrence rates of vomiting, hemoglobin decrease and blood platelet decrease of the treated group were lower than those of the control group. There existed a significant difference （P〈 0.05）. Conclusion： Shengbai He weihaishen Oral Liquid has the function of increasing the number of leukocyte and decrease the toxic and side effects of chemotherapy.